{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:07:14Z","timestamp":1773392834466,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Ultrasonics"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Tolvaptan is the first approved treatment for autosomal dominant polycystic kidney disease (ADPKD) that targets a mechanism directly contributing to the development and growth of renal cysts. We investigated the ability of ultrasonography to predict total kidney volume (TKV) of 750\u00a0mL or more, which is an indication for tolvaptan therapy in patients with ADPKD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 46 patients with ADPKD were evaluated. The most statistically appropriate measurement based on ultrasonography for predicting TKV determined by computed tomography (CT) was assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>TKV determined by CT was 796.8 (508.8\u20131,560.3)\u00a0mL. The median length, anteroposterior distance, and mediolateral distance determined using ultrasonography were 15.7\u00a0cm, 7.6\u00a0cm, and 7.6\u00a0cm in the left kidney, and 13.4\u00a0cm, 6.9\u00a0cm, and 7.2\u00a0cm in the right kidney, respectively. Multivariate regression analysis showed that total kidney length (left and right) [variance inflation factor (VIF), 9.349] and total mediolateral distance (left and right) (VIF, 3.988) were independently associated with TKV. The correlation (<jats:italic>r<\/jats:italic>) between the logarithm of TKV determined by CT and total mediolateral distance determined using ultrasonography was 0.915 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The linear regression equation was log (total kidney volume)\u2009=\u20091.833\u2009+\u20090.075\u2009\u00d7\u2009total mediolateral distance (left and right) based on ultrasonography. The area under the receiver operating characteristic curve for total mediolateral distance determined using ultrasonography to predict TKV of 750\u00a0mL or more was 0.989. Using the total mediolateral distance cut-off value of 14.2\u00a0cm, the sensitivity and specificity were 96.0% and 100.0%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Total mediolateral distance determined using ultrasonography can predict TKV in patients with ADPKD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10396-022-01261-z","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T04:27:29Z","timestamp":1667622449000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-8827","authenticated-orcid":false,"given":"Hiroko","family":"Iijima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kiriki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Higashiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michino","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Yamakado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,5]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","volume":"29","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2013an analysis of data from the ERA-EDTA registry. Nephrol Dial Transpl. 2014;29:iv15\u201325.","journal-title":"Nephrol Dial Transpl"},{"key":"1261_CR2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.014","author":"R Saran","year":"2016","unstructured":"Saran R, Li Y, Robinson B, et al. US renal data system 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.014.","journal-title":"Am J Kidney Dis"},{"key":"1261_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287\u2013301.","journal-title":"Lancet"},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1053\/j.ajkd.2015.01.030","volume":"66","author":"A Alam","year":"2015","unstructured":"Alam A, Dahl NK, Lipschutz JH, et al. Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy. Am J Kidney Dis. 2015;66:564\u201376.","journal-title":"Am J Kidney Dis"},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1261_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","volume":"88","author":"AB Chapman","year":"2015","unstructured":"Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88:17\u201327.","journal-title":"Kidney Int"},{"key":"1261_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and european renal best practice. Nephrol Dial Transpl. 2016;31:337\u201348.","journal-title":"Nephrol Dial Transpl"},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"205435811769578","DOI":"10.1177\/2054358117695784","volume":"4","author":"S Soroka","year":"2017","unstructured":"Soroka S, Alam A, Bevilacqua M, et al. Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a Canadian expert consensus. Can J Kidney Health Dis. 2017;4:2054358117695784.","journal-title":"Can J Kidney Health Dis"},{"key":"1261_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.semnephrol.2011.05.003","volume":"31","author":"AB Chapman","year":"2011","unstructured":"Chapman AB, Wei W. Imaging approaches to patients with polycystic kidney disease. Semin Nephrol. 2011;31:237\u201344.","journal-title":"Semin Nephrol"},{"key":"1261_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000463063","volume":"70","author":"MDA van Gastel","year":"2017","unstructured":"van Gastel MDA, Torres VE. Polycystic kidney disease and the vasopressin pathway. Ann Nutr Metab. 2017;70:43\u201350.","journal-title":"Ann Nutr Metab"},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","volume":"22","author":"O Devuyst","year":"2013","unstructured":"Devuyst O, Torres VE. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens. 2013;22:459\u201370.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1261_CR13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1148\/radiol.2019181830","volume":"291","author":"MU Bevilacqua","year":"2019","unstructured":"Bevilacqua MU, Hague CJ, Romann A, et al. CT of kidney volume in autosomal dominant polycystic kidney disease: accuracy, reproducibility, and radiation dose. Radiology. 2019;291:660\u20137.","journal-title":"Radiology"},{"key":"1261_CR14","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1007\/s00330-018-5918-9","volume":"29","author":"RJ Simms","year":"2019","unstructured":"Simms RJ, Doshi T, Metherall P, et al. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease. Eur Radiol. 2019;29:4188\u201397.","journal-title":"Eur Radiol"},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/sj.ki.5002338","volume":"72","author":"T Grobner","year":"2007","unstructured":"Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 2007;72:260\u20134.","journal-title":"Kidney Int"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1007\/s00330-019-06238-0","volume":"29","author":"H \u0130mamo\u011flu","year":"2019","unstructured":"\u0130mamo\u011flu H, Zarars\u0131z G, Do\u011fan S, et al. Autosomal dominant polycystic kidney disease: new role for ultrasound. Eur Radiol. 2019;29:5991\u20138.","journal-title":"Eur Radiol"},{"key":"1261_CR17","first-page":"181","volume-title":"Primer of applied regression and analysis of variance","author":"SA Glantz","year":"1990","unstructured":"Glantz SA, Slinker BK. Primer of applied regression and analysis of variance. New York: McGraw-Hill; 1990. p. 181\u2013238."},{"key":"1261_CR18","volume-title":"Fundamental statistics in psychology and education","author":"JP Guilford","year":"1956","unstructured":"Guilford JP. Fundamental statistics in psychology and education. New York: McGraw Hill; 1956."},{"key":"1261_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32\u20135.","journal-title":"Cancer"},{"key":"1261_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1126\/science.3287615","volume":"240","author":"JA Swets","year":"1988","unstructured":"Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285\u201393.","journal-title":"Science"},{"key":"1261_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48:452\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"1261_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","volume":"25","author":"VE Torres","year":"2014","unstructured":"Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014;25:18\u201332.","journal-title":"J Am Soc Nephrol"},{"key":"1261_CR23","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"1261_CR24","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","volume":"46","author":"WC O'Neill","year":"2005","unstructured":"O\u2019Neill WC, Robbin ML, Bae KT, et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the consortium of renal imaging studies in polycystic kidney disease (CRISP). Am J Kidney Dis. 2005;46:1058\u201364.","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Medical Ultrasonics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10396-022-01261-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10396-022-01261-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10396-022-01261-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T03:16:33Z","timestamp":1675307793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10396-022-01261-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,5]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s10396-022-01261-z","relation":{},"ISSN":["1346-4523","1613-2254"],"issn-type":[{"value":"1346-4523","type":"print"},{"value":"1613-2254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,5]]},"assertion":[{"value":"8 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroko Iijima, Toshifumi Tada, Mariko Hashimoto, Takashi Nishimura, Masato Kiriki, Akiko Higashiura, Aya Iwasaki, Michino Honda, Yasuyuki Nagasawa, and Koichiro Yamakado declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol complied with the Helsinki Declaration. It was approved by the institutional review board of the Hyogo College of Medicine (number 3516). We used the opt-out method to obtain informed consent in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}